Table 1 Intracellular and extracellular mechanisms mediated by PCSK9
PCSK9 location | Therapeutic agents targeting PCSK9 | Mechanisms mediated by PCSK9 |
|---|---|---|
Intracellular | siRNA (inclisiran) | 1. LDLR degradation 2. Inhibiting the degradation of apoB100 3. Inducing mitochondrial dysfunction 4. Inducing endothelial cell apoptosis |
Extracellular (circulating/plasma) | PCSK9 mAbs (evolocumab, alirocumab) | 1. LDLR degradation 2. VLDLR degradation 3. Positively correlated with chronic inflammation 4. Positively associated with platelet count/fibrinogen levels |